OOIR: Observatory of International Research

Papers

(The H4-Index of Breast Cancer Research and Treatment is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Intraoperative assessment of axillary sentinel lymph nodes by telepathology	101
Differential response of luminal and basal breast cancer cells to acute and chronic hypoxia	91
Comparative efficacy and safety of extended adjuvant endocrine therapy for hormone receptor-positive early breast cancer: a Bayesian network meta-analysis	88
Correction: Timely cancer genetic counseling and testing for young women with breast cancer: impact on surgical decision-making for contralateral risk-reducing mastectomy	74
Uncovering novel pathogenic variants and pathway mutations in triple-negative breast cancer among the endogamous mizo tribe	62
Temporal patterns of breast cancer incidence, mortality, disability-adjusted life years and risk factors in 12 South American Countries, 1990–2019: an examination using estimates from the global burde	61
The feasibility and safety of fasting-mimicking diet in breast cancer patients with chemotherapy in China	57
Area deprivation index and breast cancer outcomes among patients in Western New York	55
Therapeutic impact of 18F-FDG PET/CT for initial staging in patients with clinical stage I and IIA, HER2-positive, or triple-negative breast cancer	47
Cognitive effects of aromatase inhibitors in early breast cancer patients: a prospective study	46
Omission of anthracyclines from neoadjuvant chemotherapy for breast cancer: a population-based analysis	45
Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer	44
Neoadjuvant docetaxel, epirubicin, and cyclophosphamide with or without metformin in breast cancer patients with metabolic abnormality: results from the randomized Phase II NeoMET trial	43
Outcomes of male patients with HR+/HER2– advanced breast cancer receiving palbociclib in the real-world POLARIS study	42
Changes in expression of breast cancer tumor biomarkers between primary tumors and corresponding metastatic sites: common patterns and relationships with survival	37
Premenopausal women with breast cancer in the early post-partum period show molecular profiles of invasion and are associated with poor prognosis	36
The association between cirrhosis and outcomes among female patients undergoing surgery for breast cancer in Ontario: a population-based study	34
Oncotype DX recurrence score in node-positive patients in the post-RxPONDER era: a single-institution experience	33
Predicting the likelihood of carrying BRCA1 or BRCA2 pathogenic variants in high-risk Pakistani breast cancer patients	32
Outcomes after treatment of breast cancer during pregnancy including taxanes and/or granulocyte colony-stimulating factor use: findings from a multi-institutional retrospective analysis	31
Impact of pembrolizumab on ovarian function in young triple-negative breast cancer patients treated with chemo-immunotherapy	31
Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer	31
Integrating SENOMAC and AMAROS: a call for de-escalation	31
Long-term dietary intervention influence on physical activity in the Women’s Health Initiative Dietary Modification randomized trial	30
Impact of environmental temperature on the survival outcomes of breast cancer: A SEER-based study	30

Chronic inflammatory diseases and survival among breast cancer patients in the U.S. military health system	28
Endocrine adherence in male versus female breast cancer: a seer-medicare review	27
A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer	27
Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy	27
Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients	27